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ttp://dx.doi.org/10.1016/j.ajpath.2012.10.013Although inﬂammation plays a central role in the pathogenesis of acute lung injury, the molecular
mechanisms underlying inﬂammatory responses in acute lung injury are poorly understood, and ther-
apeutic options remain limited. CCAAT/enhancer-binding proteins, C/EBPb and C/EBPd, are expressed
in the lung and have been implicated in the regulation of inﬂammatory mediators. However, their
functions in lung pathobiological characteristics are not well characterized. Herein, we show that
C/EBPb and C/EBPd are activated in mouse lung after intrapulmonary deposition of lipopolysaccharide
(LPS). Mice carrying a targeted deletion of the C/EBPd gene displayed signiﬁcant attenuation of the
lung permeability index (lung vascular leak of albumin), lung neutrophil accumulation (myeloperox-
idase activity), and neutrophils in bronchial alveolar lavage ﬂuids compared with wild-type mice. These
phenotypes were consistent with morphological evaluation of lung, which showed reduced inﬂamma-
tory cell inﬂux and minimal intra-alveolar hemorrhage. Moreover, mutant mice expressed considerably
less tumor necrosis factor-a, IL-6, and macrophage inﬂammatory protein-2 in bronchial alveolar lavage
ﬂuids in LPS-injured lung compared with wild-type mice. In contrast, C/EBPb deﬁciency had no effect
on LPS-induced lung injury. By using small-interfering RNAemediated knockdown for C/EBPd, we
demonstrate, for the ﬁrst time to our knowledge, that C/EBPd plays a critical role for the tumor necrosis
factor-a, IL-6, and macrophage inﬂammatory protein-2 production in LPS-stimulated alveolar macro-
phages. These ﬁndings demonstrate that C/EBPd, but not C/EBPb, plays an important role in LPS-
induced lung inﬂammatory responses and injury. (Am J Pathol 2013, 182: 420e430; http://
dx.doi.org/10.1016/j.ajpath.2012.10.013)Supported by NIH grants 5R01HL092905-04 and 3R01HL092905-02S1
(H.G.), NIH grant ES014690, Flight Attendant Medical Research Institute
grant 103007 (M.W.), and the Intramural Research Program of the NIH,
National Cancer Institute, Center for Cancer Research (P.F.J.).Acute lung injury affects approximately 190,000 patients
annually in the United States.1 Despite the recent development
of protective lungventilation strategies, acute lung injury and its
severe form, acute respiratory distress syndrome, remain
leading factors of morbidity and mortality in critically ill
patients.1e4Oneof themajor cellular responses in lung initiated
by various direct and indirect stimuli is the activation of genes
encoding cytokines and other mediators that promote inﬂam-
mation. The resulting levels of pro- and anti-inﬂammatory
mediators and their balance determine the magnitude of lung
injury and outcome. Growing evidence indicates that the
expression of these inﬂammatory mediators in the lung is
regulated by a highly intricate network of transcription fac-
tors, such as NF-kB and STAT3.5e9 However, their exact
contributions to lung pathogenesis during acute lung injurystigative Pathology.
.remain largely undetermined, because most studies have been
either correlative or indirect (ie, based on various inhibitors
that may have effects on divergent signaling pathways). Thus,
one of the major roadblocks in developing treatments for acute
lung injury is the lack of basic knowledge of the transcriptional
mechanisms underlying lung inﬂammation.
The CCAAT/enhancer-binding proteins (C/EBPa, C/EBPb,
C/EBPd, C/EBPε, C/EBPg, and C/EBPz) compose a family
of basic region-leucine zipper (bZIP) transcription factors that
dimerize through a leucine zipper and bind to DNA through
Key Role of C/EBPd in Acute Lung Injuryan adjacent basic region.10e12 C/EBP proteins can generally
form homodimers and heterodimers with other family
members. The variety of C/EBP isoforms and their potential
for heterodimer formation could provide a large repertoire of
transcription factors with complex in vivo regulatory features.
C/EBPb and C/EBPd are regulators of pro-inﬂammatory
cytokines and other gene products of the acute-phase
response.11,13e19 C/EBPb and C/EBPd are structurally
similar in their DNA-binding and dimerization domains, but
differ in their transactivation domains, implying that theymay
have unique functions in response to different stimuli. BothC/
EBPb and C/EBPd are expressed in the lung.20e22 C/EBPb
and C/EBPd are not vital to baseline lung function and
development, as suggested by the ﬁnding that mice lacking
both C/EBPb and C/EBPd exhibit no histological abnor-
malities of the lung.23 Levels of bothC/EBPb andC/EBPd are
increased in the lung after systemic endotoxin administra-
tion.24,25 By using a gene expression proﬁling approach,
a recent study identiﬁed C/EBPd as a potential candidate
regulator of endotoxin-induced disseminated intravascular
coagulation.26 However, the functions of C/EBPb and C/
EBPd in acute lung inﬂammation remain poorly understood.
C/EBPb was recently shown to mediate inﬂammatory and
innate immune responses in lung to cigarette smoke.27
C/EBPb also reportedly played an essential role in
bleomycin-induced pulmonaryﬁbrosis.28 The role ofC/EBPd
in lung inﬂammation and injury remains unknown. Herein,
we identify C/EBPd, but not C/EBPb, as a critical regulator of
inﬂammatory responses in lipopolysaccharide (LPS)e
induced acute lung injury.
Materials and Methods
Cells and Reagents
Mouse alveolar macrophageederived cell line, MH-S, was
obtained from ATCC (Manassas, VA); cultured in RPMI
1640 medium, supplemented with 10% fetal bovine serum,
2 mmol/L L-glutamine, 100 U/mL penicillin, 100 mg/mL
streptomycin, and 0.01 mol/L HEPES; and maintained in
a humidiﬁed incubator at 37C with 5% CO2. Enzyme-
linked immunosorbent assay (ELISA) kits for mouse IL-6,
tumor necrosis factor (TNF)-a, macrophage inﬂammatory
protein (MIP)-2, and keratinocyte cellederived chemokine
(KC) were obtained from R&D Systems (Minneapolis,
MN). p38 Mitogen-activated protein kinase (MAPK)
inhibitor VIII and p44/p42 inhibitor, U0126, were obtained
from EMD Biosciences (Gibbstown, NJ).
LPS-Induced Acute Lung Injury
All procedures involving mice were approved by the Animal
Care andUseCommittee ofHarvardMedical School (Boston,
MA). Speciﬁc pathogen-free male C57BL/6 mice, aged 8 to
12 weeks, were obtained from Jackson Laboratories (Bar
Harbor, ME). Mice were anesthetized i.p. with 100 mg/kgThe American Journal of Pathology - ajp.amjpathol.orgketamine HCl, followed by intratracheal instillation of 50 mL
of LPS (1 mg/mL serotype 0111.B4; Sigma-Aldrich, St.
Louis, MO) dissolved in PBS during inspiration. Negative
control mice received 50 mL of PBS intratracheally. Unless
otherwise indicated, 18 hours after LPS deposition,micewere
exsanguinated and the pulmonary circulation was ﬂushed
with 1 mL of PBS via the pulmonary artery. The lungs were
surgically dissected and immediately frozen in liquid
nitrogen. The generation ofC/EBPb/ andC/EBPd/mice
by homologous recombinationwas previously described.29,30
Cebpb/ mice and wild-type (WT) littermates were on
a C57BL/6:Sv129 F1 hybrid background (to circumvent low
mutant viability on each pure strain background), and
Cebpd/ animals and WT controls were on a C57Bl/6
background.
MPO Activity
Mice were sacriﬁced, and the lungs were perfused via the
right ventricle with 3 mL of PBS. To measure myeloper-
oxidase (MPO) activity, whole lungs were homogenized
in 50 mmol/L potassium phosphate buffer containing
0.5% hexadecyltrimethylammonium bromide and 5 mmol/L
EDTA. The samples were sonicated for 1 minute and
centrifuged at 9600  g for 10 minutes. A total of 10 mL of
the recovered supernatants was added to a 96-well plate,
followed by the addition of 100 mmol/L potassium phos-
phate buffer containing 1.5 mol/L H2O2 and 167 mg/mL
o-dianisidine dihydrochloride. The enzyme activity was
determined by measuring the change in OD at 450 nm over
4.5 minutes using a 96-well plate reader.
Histological Assay
At 18 hours after LPS deposition, 1 mL of 10% buffered
(pH 7.2) formalin was instilled into the lung via the trachea.
The lungs were then surgically removed and further ﬁxed in
10% buffered formalin solution for morphological assay by
tissue sectioning and staining with H&E.
BAL Fluid Collection, Differential White Blood Cell
Counts, and Albumin and Chemokine/Cytokine ELISAs
At 18 hours after initiation of the acute lung injury, the thorax
was opened and 0.8 mL of ice-cold, sterile PBS was instilled
into the lung via a tracheal incision. The recovered bronchial
alveolar lavage (BAL) ﬂuid was centrifuged at 450  g for
6 minutes, and the cell-free supernatants were stored at
20C. Cell pellets were resuspended in 1 mL of HBSS
containing 0.5% bovine serum albumin, and differential cell
analyses were performed by Diff-Quikestained cytospin
preparations (Dade, Düdingen, Switzerland), counting 300
cells per slide in randomly selected high-powered ﬁelds
(original magniﬁcation, 1000). The supernatant was used
for chemokine and cytokine measurements by sandwich
ELISA. Mouse albumin levels in BAL ﬂuid were measured421
Yan et alusing a mouse albumin ELISA kit obtained from Bethyl
Laboratories (Montgomery, TX).
Alveolar Macrophage Depletion
Mice were anesthetized with 100 mg/kg i.p. ketamine
HCl. A suspension of dichloromethylene diphosphonate
(Cl2MDP) liposomes in PBS (10 mL of the liposome stock
in a total volume of 50 mL) was administered intratracheally
during inspiration. As a control, PBS liposomes were
administered in a similar manner. All subsequent interven-
tions were performed 24 hours after liposome instillation.
Liposome-encapsulated clodronate was prepared as previ-
ously described.31 Mice receiving Cl2MDP liposomes
showed >75% depletion of alveolar macrophages compared
with mice receiving PBS liposomes. The administration of
PBS liposomes did not reduce the number of alveolar
macrophages.
Assessment of C/EBP Activation by EMSA
Nuclear extracts of whole lung tissues were prepared as
previously described.21 Brieﬂy, frozen lungs were homog-
enized in 0.6% (v/v) Nonidet P-40, 150 mmol/L NaCl, 10
mmol/L HEPES (pH 7.9), 1 mmol/L EDTA, 0.5 mmol/L
phenylmethylsulfonyl ﬂuoride, 2.5 mg/mL leupeptin,
5 mg/mL antipain, and 5 mg/mL aprotinin. The homogenate
was incubated on ice for 5 minutes and then centrifuged for
5 minutes at 5000  g at 4C. Proteins were extracted
from the pelleted nuclei by incubation at 4C with solution
B [420 mmol/L NaCl, 20 mmol/L HEPES (pH 7.9),
1.2 mmol/L MgCl2, 0.2 mmol/L EDTA, 25% (v/v) glycerol,
0.5 mmol/L dithiothreitol, 0.5 mmol/L phenylmethy-
lsulfonyl ﬂuoride, 2.5 mg/mL leupeptin, 5 mg/mL antipain,
and 5 mg/mL aprotinin]. Nuclear debris was pelleted by
centrifugation at 13,000  g for 30 minutes at 4C, and the
supernatant extract was collected and stored at 80C.
Protein concentrations were determined by a Bio Rad
protein assay using bovine serum albumin as a reference
standard (Pierce Co, Rockford, IL). The electrophoretic
mobility shift assay (EMSA) probes were double-stranded
oligonucleotides containing a C/EBP consensus oligonu-
cleotide (50-TGCAGATTGCGCAATCTGCA-30; Santa Cruz
Biotechnology, Santa Cruz, CA). C/EBP probes were
labeled with [32P] ATP (3000 Ci/mmol at 10 mCi/mL)
(Amersham Biosciences Corp, Sunnyvale, CA). DNA-
binding reactions were performed at room temperature in
a 25-mL reaction mixture containing 6 mL of nuclear extract
(1 mg/mL in buffer C or solution B) and 5 mL of ﬁve times
binding buffer [20% (w/v) Ficoll, 50 mmol/L HEPES
(pH 7.9), 5 mmol/L EDTA, and 5 mmol/L dithiothreitol].
The remainder of the reaction mixture contained KCl at
a ﬁnal concentration of 50 mmol/L, Nonidet P-40 at a ﬁnal
concentration of 0.1%, 1 mg of poly(dI-dC), 200 pg of probe
(unless otherwise noted), bromphenol blue at a ﬁnal
concentration of 0.06% (w/v), and water to a volume of42225 mL. Samples were electrophoresed through 5.5% poly-
acrylamide gels in one times TBE (90 mmol/L Tris base, 90
mmol/L boric acid, and 0.5 mmol/L EDTA) at 190 V for
approximately 3.5 hours, dried under a vacuum, and
exposed to X-ray ﬁlm. For supershifts, nuclear extracts were
pre-incubated with antibodies (1 to 2 mg) for 0.5 hours at
4C before the binding reaction. The following antibodies
were obtained from Santa Cruz Biotechnology, Inc.: C/
EBPa, C/EBPb, C/EBPd, C/EBPε, C/EBPg, and normal
rabbit IgG.siRNA Transfection
Transient small-interfering RNA (siRNA) transfections
were performed by transfecting 1  106 to 2  106 MH-S
cells with control siRNA or C/EBPd siRNA (Santa Cruz
Biotechnology) using Amaxa nucleofector kit V. After 12
hours, MH-S cells were treated with or without 100 ng/mL
LPS (Sigma-Aldrich) for 6 hours. RNAs were harvested for
RT-PCR to analyze down-regulation of C/EBPd expression,
or supernatants were collected for ELISAs.Luciferase Assay
MH-S cells were transfected with the indicated reporter
plasmids by using the Fugene6 Transfection Reagent
(Roche, Indianapolis, IN). At 48 hours after transfection,
cells were treated with or without 100 ng/mL LPS. After
4 hours, cells were lysed in Passive Lysis 5X Buffer
(Promega, Madison, WI), and luciferase activity was
measured. The mouse IL-6 promoter-reporter, the TNF-
a promoter-reporter, and the C/EBPd expression plasmid
have been described in our previous publications.32,33RNA Isolation and Detection of mRNA by RT-PCR
Total RNAs were extracted from lungs with TRIzol
(Invitrogen, Carlsbad, CA), according to the manufac-
turer’s procedure. After isolation, total cellular RNA was
incubated with RQ1 RNase-free DNase (Promega) to
remove contaminating DNA. A total of 2 mg of total RNA
was submitted to reverse transcription by using the
Superscript II RNase H-Reverse Transcriptase (Invitrogen).
PCR was performed with primers for the following:
C/EBPä, 50-CGCAGACAGTGGTGAGCTT-30 (forward)
and 50-CTTCTGCTGCATCTCCTGGT-30 (reverse); and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 50-
GCCTCGTCTCATAGACAAGATG-30 (forward) and
50-CAGTAGACTCCACGACATAC-30 (reverse). After a
hot start for 5 minutes at 94C, 28 to 33 cycles were used
for ampliﬁcation, with a melting temperature of 94C, an
annealing temperature of 60C, and an extending temper-
ature of 72C, each for 1 minute, followed by a ﬁnal
extension at 72C for 8 minutes. PCR was performed using
different cycle numbers for all primers, to ensure that DNAajp.amjpathol.org - The American Journal of Pathology
Figure 1 Lung C/EBP activation during LPS-induced alveolitis. A: Time
course for C/EBP activation in LPS-injured lungs. Nuclear extracts from
whole lung tissues were subjected to EMSA analysis using a labeled
canonical C/EBP site probe. B: Nuclear proteins extracted from whole lung
at 0 and 3 hours after LPS deposition were subjected to supershift. The
following antibodies were used: normal rabbit IgG (N), anti-C/EBPa anti-
body (a), anti-C/EBPb antibody (b), anti-C/EBPd antibody (d), anti-C/EBPε
antibody (ε), and anti-C/EBPg antibody (g). Supershifted species and
C/EBP dimers are indicated. C: Western blot analysis of C/EBPb and C/EBPd
during LPS-induced lung injury. D: Effects of alveolar macrophage depletion
on C/EBP activation during LPS-induced lung injury. Mice received PBS-
liposome or Cl2MDP-liposomes 24 hours before intratracheal challenge
with either PBS or LPS. At 3 hours after PBS or LPS challenge, lungs were
harvested. C/EBP binding activity in whole lung nuclear extracts was
assessed by EMSA. LAP, liver-enriched activator protein; LIP, liver-enriched
inhibitory protein.
Key Role of C/EBPd in Acute Lung Injurywas detected within the linear part of the amplifying curves
for both primers.
Western Blot Analysis
MH-S cells were lysed in radioimmune precipitation assay
buffer. Samples containing 80 mg of protein were electro-
phoresed in a 12% polyacrylamide gel and then transferred
to a polyvinylidene diﬂuoride membrane. Membranes were
incubated with rabbit anti-C/EBPd antibody (Santa Cruz
Biotechnology), rabbit antiephospho-p38 MAPK antibody
(Cell Signaling, Danvers, MA), rabbit antiephospho-p44/42
MAPK antibody (Cell Signaling), rabbit anti-p38 MAPK
antibody (Cell Signaling), rabbit anti-p44/42 antibody
(Cell Signaling), and rabbit antieGAPDH antibody (Cell
Signaling). After three washes in Tris-buffered saline with
Tween, the membranes were incubated with a 1:5000
dilution of horseradish peroxidaseeconjugated donkey anti-
rabbit IgG (GE Healthcare, Woburn, MA). The membrane
was developed by the enhanced chemiluminescence tech-
nique, according to the manufacturer’s protocol (Thermo
Fisher Scientiﬁc, Rockford, IL).
Statistical Analysis
All values were expressed as themean SEM.Data sets were
analyzed using the Student’s t-test or a one-way analysis of
variance, with individual group means being compared with
the Student-Newman-Keuls multiple comparison test.
Results
Activation of C/EBPs during LPS-Induced Acute Lung
Injury
The time course of C/EBP activation during LPS-induced
lung injury was evaluated by EMSA, using nuclear extracts
from whole lung obtained at various time points after the
onset of lung injury. As shown in Figure 1A, at time 0, low
levels of constitutive C/EBP DNA-binding species in whole
lung nuclear extracts were observed. Increased C/EBP DNA
binding was evident and strong by 3 to 24 hours. Antibody
supershift assays were used to identify individual C/EBP
family members present in the EMSA complexes. There are
three DNA-binding species in the nuclear proteins of control-
treated lungs (PBS): a low, but detectable, level of C/EBPa/
b heterodimers, heterodimers between C/EBPb liver-enriched
activator protein and its short isoform, liver-enriched inhibi-
tory protein, which is translated from an alternative start site
in the same mRNA,34 and liver-enriched inhibiting protein/
liver-enriched inhibiting protein homodimers (Figure 1B).
However, little C/EBPd DNA binding was evident. In
contrast, the binding activities of both C/EBPb and C/EBPd
were signiﬁcantly induced in LPS-injured lungs (Figure 1B).
We next evaluated whether LPS induced expression of
C/EBPb and C/EBPd at the protein level. Western blotThe American Journal of Pathology - ajp.amjpathol.organalysis of lysates harvested over a time course after LPS
deposition revealed increased abundance of both C/EBPb and
C/EBPd during the 24-hour period (Figure 1C and data not
shown). Thus, increased expression of the C/EBPb and C/
EBPd proteins coincided with their enhanced DNA-binding
activity in the lung. To localize the expression of C/EBPd
protein, we performed immunohistochemical staining in lung
sections after LPS administration. We found strong staining
for C/EBPd protein in LPS-injured lung, especially in bron-
chiolar and alveolar epithelium (data not shown). We further
performed immunocytostaining experiments using cells in
BAL ﬂuids harvested from lungs after LPS administration.
Strong C/EBPd expression was detectable in alveolar
macrophages (data not shown).
A previous study demonstrated that alveolar macrophage
was a critical component for initiation of the LPS-induced
innate immune response in the lung.35 We sought to
determine the role of macrophages in regulating C/EBP423
Figure 2 Effects of C/EBPd deﬁciency on LPS-induced acute lung
injury. At 18 hours after LPS deposition, BAL ﬂuids (BALFs) and whole
lungs were harvested. A: Mouse albumin content in BAL ﬂuids was
determined using ELISA as an index of lung microvascular permeability.
B: Changes in lung MPO activity were measured as an index of lung
neutrophil accumulation. CeE: Leukocytes were quantitated in BAL
ﬂuids. The total numbers of leukocytes (C), neutrophils (D), and
macrophages (E) are shown. The data are expressed as mean  SEM;
n Z 3 for control-treated groups, and n Z 5 for injured groups. FeI:
Sections from lungs harvested 18 hours after PBS or LPS deposition in WT
and C/EBP-deﬁcient mice were stained with H&E. Representative sections
for each condition are shown. Lung sections shown include the
following: C/EBPdþ/þ þ PBS (F), C/EBPd/ þ PBS (G), C/EBPdþ/þ þ
LPS (H), and C/EBPd/ þ LPS (I). Original magniﬁcation, 200. *P <
0.05, **P < 0.01.
Yan et alactivation in whole lung tissues in response to LPS. Nuclear
extracts from whole lungs harvested 3 hours after the onset
of injury were analyzed by EMSA. As shown in Figure 1D,
strong LPS-induced C/EBP activation in the lung occurred
in mice pretreated with PBS liposomes. In contrast, mice
pretreated with Cl2MDP liposomes showed signiﬁcantly
reduced lung C/EBP activation after LPS instillation
(Figure 1D), suggesting that alveolar macrophages played
a critical role in lung C/EBP activation induced by LPS.
Effects of C/EBPd Deﬁciency on LPS-Induced Lung
Injury
By using systems biology approaches, Litvak et al36
recently reported that C/EBPd played a critical role in
a regulatory circuit that discriminated between transient and
persistent Toll-like receptor (TLR) 4einduced signals.
Nevertheless, the role of C/EBPd in acute lung injury
remained largely unknown. To examine whether C/EBPd
was involved in lung injury after LPS deposition, we ﬁrst
measured leakage of mouse albumin into the lungs of wild-
type and C/EBPd-deﬁcient mice. Endogenous mouse
albumin levels in BAL ﬂuids were determined by ELISA.37
As shown in Figure 2A, albumin levels in BAL ﬂuids were
signiﬁcantly increased in WT mice that received intra-
tracheal administration of LPS. However, the BAL ﬂuid
albumin levels in C/EBPd-deﬁcient mice remained at nearly
background levels (Figure 2A). We also examined MPO
content to evaluate neutrophil accumulation in the lung. As
shown in Figure 2B, C/EBPd deﬁciency alone did not cause
a change in MPO activity in the lung. LPS administration
led to increased MPO activity in WT mice, whereas MPO
content in LPS-treated C/EBPd-deﬁcient mice was modestly,
but signiﬁcantly (P < 0.05), reduced relative to WT mice
(Figure 2B).
We next evaluated the effects of C/EBPd deﬁciency on
leukocyte content in BAL ﬂuids from LPS-injured lung.
As shown in Figure 2, C andD, injured lungs fromWT andC/
EBPd-deﬁcient mice contained mostly neutrophils (93.8%
and 76%, respectively), followed by macrophages (6% and
24%, respectively). Other cell types were present in insig-
niﬁcant numbers. More important, C/EBPd-deﬁcient mice
displayed fewer neutrophils (P< 0.05, Figure 2D) compared
withWTmice. Moreover, in the lung injury groups,C/EBPd-
deﬁcient mice displayed a signiﬁcant increase in BAL
macrophages relative to WT mice (P < 0.05) (Figure 2E).
We further evaluated whether C/EBPd-deﬁcient mice
exhibited reduced lung injury, as judged by histological
criteria. As shown in Figure 2, F and G, WT and C/EBPd-
deﬁcient mice receiving PBS alone exhibited normal
lung architecture. As expected, LPS instillation led to
a strong lung hemorrhage and inﬂammatory cell inﬂux inWT
mouse lung (Figure 2H). In contrast, lungs from C/EBPd-
deﬁcient mice showed signiﬁcantly decreased neutrophil
accumulation and negligible intra-alveolar hemorrhage after
LPS instillation (Figure 2I). Collectively, the data of424 ajp.amjpathol.org - The American Journal of Pathology
Key Role of C/EBPd in Acute Lung InjuryFigures 2, 3, and 4 showed that C/EBPd plays a critical role in
LPS-induced acute lung injury.
Production of Cytokines and Chemokines in Lung after
LPS Deposition in WT, C/EBPd-Deﬁcient Mice
We examined whether the decreases in BAL neutrophils and
reduced lung injury in C/EBPd-deﬁcient mice were associ-
ated with altered levels of inﬂammatory mediators in lung.
The contents of TNF-a, IL-6, and MIP-2 in BAL ﬂuids were
determined. As expected, WT mice subjected to LPS
deposition showed dramatically increased levels of TNF-a,
IL-6, and MIP-2 compared with controls (Figure 3, AeC).
In the lung injury groups, the levels of these inﬂammatory
mediators in C/EBPd-deﬁcient mice were signiﬁcantly
decreased by 85% (TNF-a, P < 0.01) (Figure 3A), 60%
(IL-6, P < 0.001) (Figure 3B), and 45% (MIP-2, P < 0.001)
(Figure 3C), relative to WT animals.
C/EBPb Deﬁciency Does Not Affect LPS-Induced Lung
Injury
Because C/EBPb DNA-binding activity was also signiﬁ-
cantly induced by LPS in the lung (Figure 1B), we evalu-
ated whether C/EBPb was involved in LPS-induced lung
inﬂammation. WT and C/EBPb-deﬁcient mice receivingControl LPS
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Figure 3 Effects of C/EBPd and C/EBPb deﬁciency on LPS-induced producti
18 hours after onset of LPS-induced lung injury in WT, C/EBPd-deﬁcient mice (Ae
the levels of TNF-a (A and D), IL-6 (B and E), and MIP-2 (C and F) in BAL ﬂuids. R
group) mice. ***P < 0.001.
The American Journal of Pathology - ajp.amjpathol.orgPBS alone exhibited normal lung architecture. In contrast to
C/EBPd-deﬁcient mice, LPS-injured lungs from C/EBPb-
deﬁcient mice showed neither signiﬁcantly decreased
neutrophil accumulation nor reduced intra-alveolar hemor-
rhage when compared with WT injured mice (see
Supplemental Figure S1). Consistently, BAL ﬂuids from
LPS-injured lungs of C/EBPb-deﬁcient mice showed no
signiﬁcant decrease in IL-6 and MIP-2 levels when
compared with WT mice (Figure 3, E and F). Interestingly,
C/EBPb deﬁciency led to an increase in TNF-a production
in BAL ﬂuids of injured lung when compared with WT
mice (Figure 3D), suggesting that C/EBPb might have an
inhibitory effect on TNF-a expression in this setting.
Together, our data suggested that, among the C/EBP proteins,
C/EBPd speciﬁcally mediated LPS-induced inﬂammation and
injury in the lung.Effects of C/EBPd Knockdown on Cytokine and
Chemokine Protein Production in LPS-Stimulated
Alveolar Macrophages
C/EBPd activation might play a critical role in LPS-induced
inﬂammatory response in the alveolar macrophages. To
further address this possibility, we determined the effects of
C/EBPd knockdown on LPS-stimulated production of
inﬂammatory mediators in the alveolar macrophage cell line,Control LPS
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Figure 4 Effects of C/EBPd knockdown on LPS-induced production of cytokines and chemokines from alveolar macrophage cells. MH-S cells were tran-
siently transfected with 40 nmol/L control siRNA or C/EBPd siRNA. At 12 hours after transfection, the cells were incubated with 100 ng/mL LPS for 6 hours.
Supernatants were harvested, and an ELISA was performed to determine the expressions of TNF-a (A), IL-6 (B), and MIP-2 (C). The data are expressed as mean
 SEM (n Z 9 to 10). **P < 0.01, ***P < 0.001.
Yan et alMH-S. C/EBPd expression was efﬁciently down-regulated
by siRNA speciﬁc for C/EBPd in MH-S cells, but the same
siRNA had no inhibitory effect on C/EBPb expression (data
not shown). Notably, there was a signiﬁcant reduction in
LPS-induced cytokine and chemokine production after C/
EBPd ablation inMH-S cells: TNF-a decreased by 62%, IL-6
decreased by 77%, and IL-6 and MIP-2 decreased by 48%
(Figure 4). These results suggested that C/EBPd in alveolar
macrophages signiﬁcantly contributed to the LPS-elicited
inﬂammatory responses in the lung.
Effects of C/EBPd Overexpression on LPS-Induced
TNF-a and IL-6 Expression in Alveolar Macrophages
We next evaluated the LPS-induced C/EBP activation in
transient transfection assays (Promega) using 2XC/EBP-Luc,
a promoter-reporter that contains two copies of a C/EBP
binding site, and an expression vector for C/EBPd. These
transfections were performed in MH-S cells, with and
without LPS treatment. Consistent with the results from
EMSA (Figure 1), LPS stimulation alone (without trans-
fection of a C/EBPd expression vector) induced a 3.15-fold0.0
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Figure 5 Effects of C/EBPd expression on LPS-induced activity of the C/EBP
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426increase in luciferase activity compared with untreated cells
(Figure 5A). The C/EBPd vector alone, in the absence of
LPS stimulation, also elevated transcription from the
reporter (2.3-fold), whereas LPS treatment of C/EBPd-
transfected cells induced luciferase expression 5.66-fold
over the reporter alone. Thus, LPS or ectopic C/EBPd
expression could stimulate a C/EBP-dependent promoter in
alveolar macrophages.
We also assessed the ability of C/EBPd to regulate LPS-
induced TNF-a and IL-6 expression in transient transfections
using TNF-a-Luc and IL-6-Luc, two promoter-reporters that
contain C/EBP binding sites, and a C/EBPd expression
vector. These transfections were performed with and without
LPS treatment. LPS alone signiﬁcantly increased luciferase
activity (3.2-fold for TNF-a and 1.85-fold for IL-6) compared
with controls (Figure 5, B and C). Moreover, C/EBPd
overexpression, in the absence of LPS stimulation, resulted in
1.3-fold (TNF-a) and 1.58-fold (IL-6) induction of luciferase
activity. Importantly, LPS treatment of C/EBPd transfectants
induced TNF-a and IL-6 luciferase expression by 7.2-fold
and 4.5-fold, respectively, over the control values. Because
the effects of LPS and C/EBPd together on these promoters0.0
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Figure 6 Both p44/p421 and p38 MAPK are involved in LPS-induced
C/EBPd expression in alveolar macrophages. A and B: MH-S cells were
treated with 100 ng/mL LPS in the presence or absence of p44/42 MAPK
inhibitor, U0126 (10 mmol/L) (A), or p38 MAPK inhibitor VII (10 mmol/L)
(B) for the indicated time periods. Total proteins were subjected to Western
blot analysis by using rabbit antiephospho-p44/42 (p-p44/42) antibody,
rabbit anti-p44/42 antibody, rabbit antiephospho-p38 antibody (p-p38),
and rabbit anti-p38 antibody. C and D: MH-S cells were treated with 100
ng/mL LPS, LPS plus p44/42 inhibitor, U0126 (10 mmol/L), or LPS plus p38
MAPK inhibitor VII (10 mmol/L) for 4 hours. The nuclear proteins were
extracted to perform Western blot analysis. Non-speciﬁc bands were shown
at the bottom as the loading control. DMSO, dimethyl sulfoxide.
Key Role of C/EBPd in Acute Lung Injurywere more than additive, LPS might stimulate C/EBPd
activity and its expression in alveolar macrophages.
Extracellular SignaleRegulated Kinase 1/2 and p38
MAPK Are Involved in LPS-Induced C/EBPd Expression
and Cytokine/Chemokine Production in Alveolar
Macrophages
We evaluated the MAPK pathways in LPS-stimulated MH-
S cells. As shown in Figure 6, A and B, LPS treatment led to
the phosphorylation of both p44/42 and p38 MAPK in
a time-dependent manner. We determined the inﬂuence ofControl LPS
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Figure 7 Both p44/p42 and p38 MAPK are involved in LPS-induced cytokine/ch
with 100 ng/mL LPS in the presence or absence of p44/42 MAPK inhibitor, U012
Supernatants were subjected to ELISA analysis for TNF-a (A), IL-6 (B), and MIP-2
dimethyl sulfoxide.
The American Journal of Pathology - ajp.amjpathol.orgthe MAPK phosphorylation on nucleus C/EBPd expression
by using speciﬁc pharmacological inhibitors for p44/42 and
p38 MAPK. Phosphorylation of p44/42 and p38 MAPK was
signiﬁcantly inhibited by U0126 and p38 MAPK inhibitor
VIII, respectively (Figure 6, A and B). Furthermore, U0126
and p38 MAPK inhibitor VIII markedly suppressed the
nuclear C/EBPd level induced by LPS (Figure 6, C and D).
We further determined the effect of U0126 and p38
MAPK inhibitor VIII on TNF-a, IL-6, and MIP-2 produc-
tion in MH-S cells. U0126 and p38 MAPK inhibitor VIII
signiﬁcantly inhibited LPS-stimulated TNF-a, IL-6, and
MIP-2 production (Figure 7, AeC). Furthermore, when
MH-S cells were treated with p44/42 and p38 inhibitors
together, the production of TNF-a, IL-6, and MIP-2 was at
undetectable levels (Figure 7, AeC), suggesting that p44/42
and p38 MAPK acted in concert to mediate the LPS signal
in alveolar macrophages.
Discussion
LPS is the major outer surface membrane component
present in Gram-negative bacteria and is strong stimulator of
innate immunity.38 LPS has been administered to humans
via the intratracheal route, which resulted in an early phase
reaction characterized by increases in BAL ﬂuid neutro-
phils, albumin, and pro-inﬂammatory mediators (eg, TNF-a,
IL-6, and MIPs) and a later phase reaction (24 to 48 hours
after instillation) characterized by normalization of the BAL
ﬂuid cytokine concentrations.39 In vivo animal studies of
LPS-induced lung injury are widely used as experimental
approaches to investigate the mechanisms of acute lung
inﬂammatory injury. This animal model displays key
features of microvascular injury, as seen in patients with
acute respiratory distress syndrome.40 Furthermore, LPS is
a potent activator of the innate immune responses via TLR4
pathways, and the use of LPS provides information about
the effects of host inﬂammatory responses, which occur
during bacterial infections.41 Despite its wide use, the
underlying pathophysiological mechanisms for the LPSControl LPS
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6 (10 mmol/L), p38 MAPK inhibitor VII (10 mmol/L), or both for 8 hours.
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Yan et almodel have not been comprehensively described. In the
current study, we show that C/EBPd deﬁciency signiﬁcantly
inhibits LPS-induced acute lung injury, as deﬁned by
reduced albumin leakage into lung, MPO content, and
histological change in the lung, suggesting that C/EBPd is
a critical mediator of LPS-induced acute lung injury and
inﬂammatory response in alveolar macrophages. Impor-
tantly, we show that the role of C/EBPd in acute lung injury
is speciﬁc, because C/EBPb, a closely related family
member whose expression is also increased in the lung by
LPS stimulation (Figure 1), does not affect acute lung
inﬂammation in vivo.
Both C/EBPb and C/EBPd are involved in the regulation
of the acute phase and inﬂammatory responses.11,12 The roles
of C/EBPb and C/EBPd in regulating inﬂammation have also
been studied using knockout mice. LPS stimulation of peri-
toneal macrophages from C/EBPb-deﬁcient mice led to
normal induction of several inﬂammatory cytokines,
including IL-6 and TNF-a.42e45 Similarly, C/EBPd-deﬁcient
macrophages did not show signiﬁcant defects in IL-6 and
TNF-a production in response to several TLR ligands.46 In
contrast, the absence of both C/EBPb and C/EBPd results in
a signiﬁcant decrease in the TLR ligandeinduced production
of IL-6 and TNF-a.46 Thus, either C/EBPb or C/EBPd is
sufﬁcient to support the induction of these pro-inﬂammatory
cytokines. Indeed, C/EBPd has bound to the same DNA
sequence as C/EBPb and acted as a homodimer or hetero-
dimer with C/EBPb.47 Although C/EBP protein function has
been studied extensively in a variety of tissues, such as liver
and adipose, much less is known about the role of these
transcription factors in modulating acute inﬂammatory
response and injury in the lung. Both C/EBPb and C/EBPd
are strongly induced in LPS-injured lung (Figure 1).
Furthermore, we show that C/EBPd, but not C/EBPb, plays
an important regulatory role in LPS-induced lung inﬂam-
matory responses and injury. These data suggest that, in the
lung, C/EBPb and C/EBPd may have differential roles in
regulating the inﬂammatory responses to stimuli. Indeed, our
recent ﬁndings implicate C/EBPb as a critical regulator of
IgG immune complexeinduced inﬂammatory responses and
injury in the lung, whereas C/EBPd deﬁciency had no effect
on IgG immune complexeinduced lung injury (Yan C.,
unpublished data). These data, together with the current
ﬁndings, suggest that C/EBPb and C/EBPd differentially
regulate FcgR- and TLR-mediated inﬂammatory responses
in the lung.
Molecular regulation of lung inﬂammatory response to
LPS is complex and involves a variety of relatively ubiquitous
transcription factors.9 NF-kB played a key role in the tran-
scriptional up-regulation of many inﬂammation-associated
genes induced by LPS. In the lung, the NF-kB pathway in
airway epithelial cells may be critical for the generation of
pulmonary inﬂammation and injury in response to local and
systemic LPS stimuli.48 NF-kB interacts with many heterol-
ogous transcription factors, and these interactions can select
for speciﬁc NF-kB subunits and, thereby, lead to greater428transcriptional selectivity.9 For example, we have previously
shown that the C/EBP bZIP domain can mediate LPS
induction of IL-6 and MCP-1 in B cells.49 Furthermore, the
ability of the C/EBPb bZIP region to activate the IL-6
promoter is completely dependent on an intact NF-kB
binding site, supporting a model in which the bZIP protein
primarily functions to augment the activity of NF-kB.49 This
is consistent with a study by Stein and Baldwin,50 showing
a direct physical association of the bZIP region of C/EBPwith
the Rel homology domain of NF-kB. Therefore, in the future,
it will be interesting to investigate the molecular mechanisms
by which NF-kB subunits act in concert with members of the
C/EBP family to regulate inﬂammatory gene expression
during acute lung injury.
Several possible mechanisms may explain the impact of
the C/EBPd pathway on neutrophil recruitment into the
alveolar compartment and lung interstitium (Figures 2B and
3A) during LPS-induced lung injury. One mechanism is that
of the modulation of inﬂammatory cytokines. Another
possible mechanism of C/EBPd involvement in neutrophil
inﬁltration is its regulation of chemokine production. Our
current ﬁnding that C/EBPd deﬁciency led to a signiﬁcant
decrease in the contents of TNF-a, IL-6, and MIP-2
(Figure 5) supports both hypotheses. Conversely, C/EBPb
deﬁciency has no signiﬁcant effect on the production of
BAL cytokines and chemokines (Figure 7). This observa-
tion further implicates the critical and speciﬁc role of
C/EBPd in LPS-induced lung inﬂammation.
Activated alveolar macrophages constitute a critical
modulator of the lung inﬂammatory response through the
production of various inﬂammation-associated mediators.
The interaction of the lipid A moiety of LPS with alveolar
macrophages in the lung appears to be especially important
because subsequent cellular activation results in the release
of inﬂammatory mediators and phenotypic changes.51 By
using dichloromethylene diphosphonate (clodronate)e
mediated macrophage depletion, Koay et al35 demonstrated
that alveolar macrophages are a critical component of the
innate immune response in the lungs that regulate the
development of neutrophilic lung inﬂammation, lung
NF-kB activation, and production of cytokines and che-
mokines after administration of LPS. In the current study,
we show that siRNA-mediated knockdown of C/EBPd led
to a signiﬁcant reduction in TNF-a, IL-6, and MIP-2
production in alveolar macrophage cells on LPS stimula-
tion (Figure 6). These results suggest that C/EBPd in
alveolar macrophages plays an important regulatory role
for the LPS-induced production of inﬂammatory mediators.
It is possible that other lung cells, such as alveolar epithelial
cells, might also contribute to C/EBPd-mediated cytokine
production in the LPS-injured lung. Increasing studies
suggest that alveolar type II epithelial cells play a critical
role in regulating local lung inﬂammatory response. For
example, previous studies52e55 have suggested that alveolar
type II epithelial cells may play special roles in counter-
acting microbes by releasing cytokines and chemokines thatajp.amjpathol.org - The American Journal of Pathology
Key Role of C/EBPd in Acute Lung Injuryrecruit both dendritic cells and alveolar macrophages to the
site of infection. By using inducible transgenic mice that
express an activator or dominant inhibitor of the NF-kB
pathway in airway epithelial cells, Cheng et al48 recently
showed that activation of NF-kB in airway epithelial cells is
sufﬁcient for generating acute lung injury, and inhibition of
NF-kB activation in airway epithelium abrogates lung
inﬂammation and injury induced by LPS. Future studies
using lung epithelial cellespeciﬁc C/EBPd knockout mice
may allow us to determine whether C/EBPd activation in
airway epithelial cells is involved in the parenchymal lung
inﬂammation and injury via production of mediators, such
as TNF-a and IL-6.
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